The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event. METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to assess whether lixisenatide was noninferior as well as superior to placebo, as defined by an upper boundary of the 95% confidence interval for the hazard ratio of less than 1.3 and 1.0, respectively, for the primary composite end point of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: The 6068 patients who underwent randomization were followed for a median of 25 months. A primary end-point event occurred in 406 patients (13.4%) in the lixisenatide group and in 399 (13.2%) in the placebo group (hazard ratio, 1.02; 95% confidence interval [CI], 0.89 to 1.17), which showed the noninferiority of lixisenatide to placebo (P<0.001) but did not show superiority (P=0.81). There were no significant between-group differences in the rate of hospitalization for heart failure (hazard ratio in the lixisenatide group, 0.96; 95% CI, 0.75 to 1.23) or the rate of death (hazard ratio, 0.94; 95% CI, 0.78 to 1.13). Lixisenatide was not associated with a higher rate of serious adverse events or severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions than was placebo. CONCLUSIONS: In patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to usual care did not significantly alter the rate of major cardiovascular events or other serious adverse events. (Funded by Sanofi; ELIXA ClinicalTrials.gov number, NCT01147250.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial,14 the GLP-1–receptor agonist lixisenatide, which is shorter-acting than and structurally dissimilar to liraglutide, did not show any cardiovascular benefit in patients with diabetes and a recent acute coronary syndrome.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“The study showed that lixisenatide is not inferior, although not superior, to placebo in cardiovascular safety.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“No increased risk of heart failure hospitalization has been identified in the cardiovascular outcomes trials of the GLP-1 RAs lixisenatide, liraglutide, semaglutide, exenatide once weekly, albiglutide, or dulaglutide compared with placebo (261,264,265,296,297).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [297]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [641]
Experimental — accuracy not yet measuredIn the citing paper
“The indication is to effectively reduce glycosylated hemoglobin levels in patients with T2DM by reducing fasting and postprandial blood glucose levels (61, 62).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [61]
In the citing paper
“In the ELIXA trial, lixisenatide 10 or 20 μg o.d. was non-inferior to placebo, but did not significantly affect a four-point MACE (three-point MACE plus hospitalization for unstable angina) in patients with T2DM post-ACS.158”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“Most GLP-1 RAs had a neutral effect on risk of HF hospitalization in the placebo-controlled RCTs assessing CV safety of glucose-lowering medications in patients with T2DM with or at high risk of ASCVD, despite increasing heart rate by 3-5 b.p.m. 70,72,158- 163,544”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF. 70,158-164,545 IIa A”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [158]
In the citing paper
“ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) was the first to report and showed that the short-acting GLP-1 receptor agonist lixisenatide had no impact on MACEs in 6068 patients after an acute coronary syndrome.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [224]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“The primary outcome of cardiovascular death, MI, stroke, or hospitalization for unstable angina occurred in 406 patients (13.4%) in the lixisenatide group vs. 399 (13.2%) in the placebo group (HR 1.2 [95% CI 0.89 -1.17]), which demonstrated the noninferiority of lixisenatide to placebo ( P < 0.001) but did not show superiority ( P = 0.81).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“No increased risk of heart failure hospitalization has been identi fi ed in the cardiovascular outcomes trials of the GLP-1 receptor agonists lixisenatide, liraglutide, semaglutide, exenatide once-weekly, albiglutide, or dulaglutide compared with placebo ( Table 10.3 B ) (203,204,207 -209).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [208]
In the citing paper
“However, two GLP-1 analogues tested in two studies demonstrated no advantage in influencing cardiovascular outcome.278,279”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [279]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
In the citing paper
“In these trials, GLP-1 receptor agonists had a neutral effect on the risk for HF hospitalization.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Cited by
Sorted by citations
Items 601–700 of 1,016
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Hu, J.-C., Shao, S., Tsai, D. H., Chuang, A. T.-M., Liu, K., & Lai, E. C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0946 · Cited by 42
Emerging roles of sodium–glucose cotransporter 2 inhibitors in cardiology
Tanaka, A., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.019 · Cited by 40
The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
Secrest, M. H., Udell, J. A., & Filion, K. B. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.01.009 · Cited by 41
Basal Glucose Can Be Controlled, but the Prandial Problem Persists—It’s the Next Target!
Riddle, M. C. (2017) · Diabetes Care · doi:10.2337/dc16-2380 · Cited by 43
Self-citationPreventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 42
Giugliano, D., Chiodini, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01047-0 · Cited by 41
Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 42
Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39
von Scholten, B. J., Kreiner, F. F., Rasmussen, S., Rossing, P. R., & Idorn, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221112490 · Cited by 41
Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines
Suckow, A. T., & Briscoe, C. P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_45 · Cited by 38
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 40
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2017.12.003 · Cited by 42
Peralta, F. G., Escalada, J., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 46
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes
Dardano, A., Miccoli, R., Bianchi, C., Daniele, G., & Prato, S. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108112 · Cited by 39
Saengboonmee, C., Seubwai, W., Lert-itthiporn, W., Sanlung, T., & Wongkham, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.008 · Cited by 40
Adamou, A. T., Barkas, F., Milionis, H. J., & Ntaios, G. (2024) · International Journal of Stroke · doi:10.1177/17474930241253988 · Cited by 38
Havranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 45
Zannad, F. M., Stough, W. G., Lipicky, R. J., Tamargo, J. L., Bakris, G. L., BORER, J. S., García, M. D. L. A. A., Hadjadj, S., Köenig, W., Kupfer, S., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw007 · Cited by 38
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 40
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Dieter, B. P., Alicic, R. Z., & Tuttle, K. R. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00211.2018 · Cited by 39
Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.51 · Cited by 37
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 40
Cardiac and Renovascular Complications in Type 2 Diabetes — Is There Hope?
Ingelfinger, J. R., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejme1607413 · Cited by 38
van der Aart‐van der Beek, A. B., Clegg, L. E., Penland, R. C., Boulton, D. W., Sjöström, C. D., Mentz, R. J., Holman, R. R., & Heerspink, H. J. L. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14175 · Cited by 37
Wu, T., Zhang, Y., Shi, Y., Yu, K., Zhao, M., Liu, S., & Zhao, Z. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01202-1 · Cited by 38
Incretin-Based Therapy for Diabetes
Waldrop, G. E., Zhong, J., Peters, M. C., & Rajagopalan, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.058 · Cited by 38
Cardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 37
Development and characterisation of a novel glucagon like peptide-1 receptor antibody
Biggs, E. K., Liang, L., Naylor, J., Madalli, S., Collier, R., Coghlan, M. P., Baker, D. J., Hornigold, D. C., Ravn, P., Reimann, F. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4491-0 · Cited by 37
Consoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 40
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6773-2 · Cited by 39
Gallwitz, B. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14.1.17 · Cited by 36
SGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 39
Zhao, Z., & Pu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.135 · Cited by 37
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
Giugliano, D., Nicola, L. D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13743 · Cited by 37
Addressing Comorbidities in Heart Failure
Bavishi, A. A., & Patel, R. B. (2020) · Heart Failure Clinics · doi:10.1016/j.hfc.2020.06.005 · Cited by 40
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 39
Piepoli, M. F., Adamo, M., Barison, A., Bestetti, R. B., Biegus, J., Böhm, M., Butler, J., Carapetis, J. R., Ceconi, C., Chioncel, O. D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab147 · Cited by 43
Self-citationImpact of glucose-lowering therapies on risk of stroke in type 2 diabetes
Bonnet, F., & Scheen, A. J. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.04.004 · Cited by 36
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Hosseinpour, A., Sood, A., Kamalpour, J., Zandi, E., Pakmehr, S., Hosseinpour, H., Sood, A., Agrawal, A., & Gupta, R. (2024) · Clinical Cardiology · doi:10.1002/clc.24314 · Cited by 40
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes
Karakasis, P., Patoulias, D., Theofilis, P., Pamporis, K., Sagris, Μ., Vlachakis, P. K., Koufakis, T., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073050 · Cited by 38
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Courtney, H., Nayar, R., Rajeswaran, C., & Jandhyala, R. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126763 · Cited by 35
Wu, S., Cipriani, A., Yang, Z., Yang, J., Cai, T., Xu, Y., Quan, X., Zhang, Y., Chai, S., Sun, F., et al. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1424826 · Cited by 36
The European Medicines Agency's approval of new medicines for type 2 diabetes
BLIND, E., Janssen, H., Dunder, K., & de Graeff, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13349 · Cited by 40
Abdelhafiz, A. H., & Sinclair, A. J. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107639 · Cited by 39
de, A. P.-M., Pellitero, S., & Puig‐Domingo, M. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03369-6 · Cited by 36
Westermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 41
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
SKOLNIK, N., & Style, A. J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01050-w · Cited by 40
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 48
Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 42
Schernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 38
Huang, M., Wei, R., Wang, Y., Su, T.-Y., Li, Q., Yang, X., & Chen, X. (2017) · Annals of Medicine · doi:10.1080/07853890.2017.1306653 · Cited by 35
Valentine, V., Goldman, J. D., & Shubrook, J. H. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0287-y · Cited by 35
Impaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus
Akoumianakis, I., & Antoniades, C. A. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7421 · Cited by 37
Fei, Y., Tsoi, M. F., Kumana, C. R., Cheung, T. T., & Cheung, B. M. Y. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.039 · Cited by 35
Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01179-1 · Cited by 35
Self-citationIncretin-based therapies in 2021 – Current status and perspectives for the future
Rizzo, M., Nauck, M. A., & Mantzoros, C. S. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154843 · Cited by 35
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 35
Qin, J., & Song, L. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01036-0 · Cited by 40
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 36
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes
Rojano‐Toimil, A., & Ciudin, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173955 · Cited by 36
Kunutsor, S. K., Khunti, K., & Seidu, S. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231198442 · Cited by 35
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 34
Treatment of Diabetes in People With Heart Failure
Connelly, K. A., Gilbert, R. E., & Liu, P. X. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.026 · Cited by 35
Giugliano, D., Maiorino, M. I., Longo, M., Bellastella, G., Chiodini, P., & Esposito, K. (2019) · Endocrine · doi:10.1007/s12020-019-01931-y · Cited by 33
Toxicity of Metformin and Hypoglycemic Therapies
Akhter, M. S., & Uppal, P. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.08.004 · Cited by 36
Webb, D. R., Htike, Z. Z., Swarbrick, D. J., Brady, E. M., Gray, L. J., Biglands, J. D., Gulsin, G. S., Henson, J. J., Khunti, K., McCann, G. P., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14023 · Cited by 34
Yamada, S., Tanabe, J., Ogura, Y., Nagai, Y., Sugaya, T., Ohata, K., Natsuki, Y., Ichikawa, D., Watanabe, S., Inoue, K., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-02007-2 · Cited by 34
How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
García-Carro, C., Vergara, A., Bermejo, S., Azancot, M. A., Sánchez-Fructuoso, A. I., de la Nieta, M. D. S., Agraz, I., & Soler, M. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112505 · Cited by 35
Yuan, D., Sharma, H., Krishnan, A., Vangaveti, V., & Malabu, U. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14776 · Cited by 35
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update
Giglio, R. V., Patti, A. M., Rizvi, A. A., Stoian, A. P., Ciaccio, M., Παπάνας, Ν., Janež, A., Sönmez, A., Banach, M., Sahebkar, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020291 · Cited by 35
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 40
Furth, S. L., Colhoun, H. M., Kanbay, M., Kukla, A., Lim, L., MacLaughlin, H. L., Navaneethan, S. D., Shroff, R. C., Stenvinkel, P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.09.019 · Cited by 45
Sassoon, D., Tune, J. D., Mather, K. J., Noblet, J. N., Eagleson, M. A., Conteh, A. M., Sturek, J. T., & Goodwill, A. G. (2017) · Diabetes · doi:10.2337/db16-1206 · Cited by 35
The regulatory role of DPP4 in atherosclerotic disease
Duan, L., Rao, X., Xia, C. Q., Rajagopalan, S., & Zhong, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0558-y · Cited by 33
GLP-1 receptor agonists: differentiation within the class
Taylor, S. I. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30413-8 · Cited by 33
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Kanie, T., Mizuno, A., Yoneoka, D., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., Wu, O., & Kwong, J. S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650 · Cited by 34
North, E. J., & Newman, J. D. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000673 · Cited by 34
Nreu, B., Dicembrini, I., Tinti, F., Mannucci, E., & Monami, M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108087 · Cited by 32
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32
Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases
Huang, W., Chen, Y., Li, Z., He, F., & Zhang, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810882 · Cited by 33
Karakasis, P., Patoulias, D., Kassimis, G., Koufakis, T., Klisic, A. N., Doumas, M. N., Fragakis, N., & Rizzo, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128304097240529053538 · Cited by 33
Skrobucha, A., Pindlowski, P., Krajewska, N., Grabowski, M., & Jonik, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1446468 · Cited by 32
Barkas, F., Elisaf, M., Tsimihodimos, V., & Milionis, H. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.10.006 · Cited by 32
Histones and heart failure in diabetes
Yerra, V. G., & Advani, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2857-1 · Cited by 33
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 35
Mishriky, B. M., Powell, J. R., Wittwer, J. A., Chu, J., Sewell, K. B., Wu, Q., & Cummings, D. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13805 · Cited by 32
Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus
Vijayakumar, S., Vaduganathan, M., & Butler, J. (2018) · Circulation · doi:10.1161/circulationaha.117.032099 · Cited by 32
Common Co-Morbidities in Heart Failure – Diabetes, Functional Mitral Regurgitation and Sleep Apnoea
Coats, A. J. S. (2019) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0004 · Cited by 32
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 32
Metadata
- Authors
- Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Solomon, S. D., & Tardif, J.-C.
- Affiliations
- Brigham and Women's Hospital (US)
- Stavanger University Hospital (NO)
- McMaster University (CA)
- Copenhagen University Hospital (DK)
- Sanofi (United States) (US)
- University of Zurich (CH)
- University of Washington Medical Center (US)
- Oregon Health & Science University (US)
- Montreal Heart Institute (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-03
- Volume
- 373
- Issue
- 23
- Pages
- 2247-2257
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2282578582
- Cited by
- 2,409
- References
- 38
- Citations by year
- 2026: 136 · 2025: 175 · 2024: 182 · 2023: 165 · 2022: 191 · 2021: 250 · 2020: 281 · 2019: 251 · 2018: 290 · 2017: 278 · 2016: 202 · 2015: 4
- FWCI
- 224.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- lixisenatide, type 2 diabetes, acute coronary syndrome, myocardial infarction, unstable angina, GLP-1 receptor agonists, cardiovascular outcomes, non-inferiority, major adverse cardiovascular events, heart failure hospitalization, serious adverse events, hypoglycemia, pancreatitis, pancreatic neoplasms, allergic reactions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Peptides, Proportional Hazards Models, Treatment Failure, Kaplan-Meier Estimate, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
